Value-Based Care

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

Fraud, waste, and abuse are key areas that can affect strategies in care delivery and can undermine the ability to give quality care.

Carl Regillo, MD, explains why wet AMD anti‑VEGF results lag in real life and how newer agents extend dosing, yet the burden persists.

NCCN added pemivibart to its lymphoma guidelines, expanding COVID-19 prevention options for immunocompromised patients.

House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research.

The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.

National HIV Testing Day highlights how state policies, pharmacists, and long-acting therapies are reshaping access to HIV testing, PrEP, and PEP.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

The message rate tripled, rising by 153% from 2020 to 2025, adding clinician workload and exposing equity gaps that managed care must address.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

Broader cancer care networks were not consistently associated with lower Medicare Advantage disenrollment after cancer diagnosis.

Commercial health care costs are projected to grow 9% in 2027, driven by AI billing tools, pharmacy spend, and provider consolidation, per a PwC report.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Forging multistakeholder partnerships and prioritizing high-impact specialities can help convert market volatility to an advantage.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

Invited commentaries on the CORAL trial praise nalbuphine's potential in IPF cough while raising questions about safety and durability.

Implementation of surgeon-led Musculoskeletal Quality Collaborative protocols reduced high-cost consumable utilization without compromising patient safety. Systemwide collaboratives can reduce high-cost consumable utilization while maintaining low infection rates.

Reports highlight gaps in private equity oversight, MA vs FFS outcomes, cancer care access advances, climate health disparities, and uneven genomic testing.

Ohio cancer care leaders identified persistent gaps in quality, pharmacy infrastructure, bispecific access, and biomarker testing at a May 2026 summit.

Medicare FFS beneficiaries with metastatic cancer received broad genomic profiling more often than MA patients.

Muhammad Bilal Abid, MD, discusses COVID-19 variant surveillance, monoclonal antibodies, and layered prevention in immunocompromised patients.